Targeted Ablation of CML Stem Cells
Abstract
The purpose of this grant project was to identify and characterize methods for ablation of chronic myelogenous leukemia (CML) stem cells. Numerous studies have shown that malignant stem cells lie at the heart of CML disease. Therefore, specific targeting of these cells is essential for more durable remission and cure. Consequently, the authors are employing both mouse and human model systems to study the nature of CML stem cells and to identify effective drug combinations that will preferentially destroy malignant stem cells while sparing normal cells. Studies to date in their mouse model system indicate that PS-341 may be a drug that effectively targets primitive CML cells. In addition, studies using primary human CML cells indicate that the naturally occurring compound parthenolide may be a useful anti-leukemia agent. The author concludes that both human and mouse CML cells are sensitive to the proteasome inhibitor drugs parthenolide and PS-341.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2005
- Accession Number
- ADA438268
Entities
People
- Craig T. Jordan
Organizations
- University of Rochester